Form 6-K INTERMAP TECHNOLOGIES For: Aug 11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2026

 

Commission File Number: 000-56743

 

 

Intermap Technologies Corporation

(Translation of registrant’s name into English)

 

385 Inverness Parkway, Suite 105

Englewood, Colorado 80112

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☐ Form 40-F ☒

 

 

 

DOCUMENTS FILED AS PART OF THIS FORM 6-K

 

Exhibit		Description
99.1		Material Change Report, dated August 7, 2026
99.2*		Arrangement Agreement, dated July 28 2026 (redacted)
99.3*		Voting Support Agreement, dated July 28, 2026 (redacted)
99.4		Form of Lock-Up Agreement

 

Exhibit 99.1 of this Report on Form 6-K is incorporated by reference into the registration statement on Form F-10 (File No. 333-290278) of the registrant.

 

* Certain identified information has been excluded from Exhibits 99.2 and 99.3 because it both (i) is not material and (ii) is customarily and actually treated as privileged or confidential information; such information is indicated by [redacted].

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	INTERMAP TECHNOLOGIES CORP.
Date: August 11, 2026
	By:	/s/ Patrick A. Blott
	Name:	Patrick A. Blott
	Title:	Chief Executive Officer

 

 

 

ATTACHMENTS / EXHIBITS

EX-99.1

EX-99.2

EX-99.3

EX-99.4

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Datavault AI Issues Statement Regarding Recent Shareholder Litigation
• CraniUS Therapeutics Receives FDA 510(k) Clearance for the CraniUS® Plate, a Patient-Specific Cranial Implant
• Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2